Chronic obstructive pulmonary disease and heart failure in Europe—further evidence of the need for integrated care

Hawkins, Nathaniel M.

doi:10.1002/ejhf.986

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This requires the appropriate use of bronchodilators, beta-blockers, and oral corticosteroids. Both beta-blockers and angiotensin-converting enzyme inhibitors remain to be underutilized mainly out of fear for bronchospasm and cough intolerance, respectively [15]. However, patients with both COPD and heart failure with a reduced ejection fraction should not be deterred from treatment with cardioselective beta-blockers, and results of this study support the potential benefit of inhibiting the renin-angiotensin-aldosterone system for hospitalizations or mortality among both COPD and CHF patients [1, 15].…”

supporting

confidence: 53%

“…Both beta-blockers and angiotensin-converting enzyme inhibitors remain to be underutilized mainly out of fear for bronchospasm and cough intolerance, respectively [15]. However, patients with both COPD and heart failure with a reduced ejection fraction should not be deterred from treatment with cardioselective beta-blockers, and results of this study support the potential benefit of inhibiting the renin-angiotensin-aldosterone system for hospitalizations or mortality among both COPD and CHF patients [1, 15]. COPD exacerbations are often treated with high-dose oral corticosteroids, which may have an impact on further cardiac decompensation due to the water-retaining effect of high-dose steroids.…”

mentioning

confidence: 99%

See 1 more Smart Citation

When the Heart Steals Your Breath Away

Lahousse

Vanfleteren

2018

Respiration

View full text Add to dashboard Cite

supporting

confidence: 53%

mentioning

confidence: 99%

When the Heart Steals Your Breath Away

Lahousse

Vanfleteren

2018

Respiration

View full text Add to dashboard Cite

“…This will gain further insight into the pathophysiology of CHF–COPD co‐morbidity by using the technology advances faster and more widely and, importantly, move on to a much closer cooperation among cardiologists and pneumonologists. This will be led hopefully by the relative Scientific Societies, as authoritative pneumonologists are strongly advising , …”

Section: New Approaches To Chronic Heart Failure–chronic Obstructive mentioning

confidence: 99%

“…This will be led hopefully by the relative Scientific Societies, as authoritative pneumonologists are strongly advising. 12,22 Conflict of interest: none declared.…”

Section: New Approaches To Chronic Heart Failure-chronic Obstructive mentioning

confidence: 99%

It's time to move on from counting co‐morbidities to curing them: the case of chronic heart failure–chronic obstructive pulmonary disease co‐morbidity

Tavazzi

2017

European J of Heart Fail

View full text Add to dashboard Cite

“…In fact, out of 100 patients with HF, at least 30 would be misdiagnosed as having COPD, and at least another 30 would have true COPD which, however, went unnoticed. 16 …”

Section: Problems Of Diagnosismentioning

confidence: 99%

Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease

Verdecchia

Cavallini

Coiro

et al. 2021

European Heart Journal Supplements

View full text Add to dashboard Cite

For many years, β-blockers have been considered contraindicated in patients with heart failure (HF) and in those with bronchial asthma or even chronic obstructive pulmonary disease (COPD) although without clear evidence of asthma. Today, despite overwhelming evidence of the usefulness of β-blockers, especially in HF with reduced left ventricular ejection fraction (HFrEF), and in ischaemic heart disease, some reluctance persists in using these drugs when COPD coexists. Such resistance is due to the fear that a possible worsening of bronchospasm induced by β-blockers could induce negative effects greater than the benefits. The Guidelines of the European Society of Cardiology clearly suggest that: (i) implantation of a cardiac defibrillator (ICD) are not contraindicated in COPD without clear evidence of bronchial asthma; (ii) β-blockers are only ‘relatively’ contraindicated when there is certainty of bronchial asthma with a documented bronchodilator response to the β2 stimulant. Therefore, bronchial asthma is not an absolute contraindication to β-blockers. The cardiologist should not limit the diagnosis of COPD to clinical suspicion, but should rely on a spirometry examination associated with any bronchodilation tests. In any case, selective β1 blockers are preferred, starting at a basic dose, which ensure a better dilator response to bronchodilators and in any case cause less bronchospasm than non-selective β-blockers. Unfortunately, there is still some reluctance to the use of β-blockers in patients with COPD associated with HF, which should be eliminated.

show abstract

Chronic obstructive pulmonary disease and heart failure in Europe—further evidence of the need for integrated care

Cited by 8 publications

References 17 publications

When the Heart Steals Your Breath Away

When the Heart Steals Your Breath Away

It's time to move on from counting co‐morbidities to curing them: the case of chronic heart failure–chronic obstructive pulmonary disease co‐morbidity

Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease

Contact Info

Product

Resources

About